A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2009
At a glance
- Drugs Entinostat (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Syndax Pharmaceuticals
- 12 Jan 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 12 Jan 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 03 Oct 2008 New trial record.